

University of Groningen

Erratum to: Health-Related Quality of Life in Patients with Multiple Sclerosis

Jongen, Peter Joseph

Published in:
 Cns Drugs

DOI:
[10.1007/s40263-017-0457-5](https://doi.org/10.1007/s40263-017-0457-5)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
 Publisher's PDF, also known as Version of record

Publication date:
 2017

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Jongen, P. J. (2017). Erratum to: Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs. *Cns Drugs*, 31(7), 603-603. <https://doi.org/10.1007/s40263-017-0457-5>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Erratum to: Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs

Peter Joseph Jongen^{1,2}

Published online: 7 July 2017
© Springer International Publishing AG 2017

Erratum to: CNS Drugs DOI 10.1007/s40263-017-0444-x

An Online First version of this article was made available online at <http://link.springer.com/journal/40263/online/First/page/1> on 12 June 2017. A number of errors were subsequently identified in the article, and the following corrections should be noted:

Page 2, column 1, line 8: The text, which previously read:

“... INFβ-1b, pegylated INFβ-1a ...” should read:
“... IFNβ-1b, pegylated IFNβ-1a ...”

Page 6, Table 2, ‘Outcome’ column, line 1: The text, which previously read:

“... LMSQOL score ...” should read:

“... LMSQoL score ...”

Page 9, column 1, line 3: The text, which previously read:

“... INFβ-1a ...” should read:
“... IFNβ-1a ...”

Page 11, column 2, line 11: The text, which previously read:

“... INFβ ...” should read:
“... IFNβ ...”

Page 11, column 2, line 20: The text, which previously read:

“... INFβ-1a ...” should read:
“... IFNβ-1a ...”

The online version of the original article can be found under doi:[10.1007/s40263-017-0444-x](https://doi.org/10.1007/s40263-017-0444-x).

✉ Peter Joseph Jongen
p.j.h.jongen@rug.nl

¹ Department of Community and Occupational Medicine, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands

² MS4 Research Institute, Ubbergseweg 34, 6522 KJ Nijmegen, The Netherlands